A new study, published by the BMJ (British Medical Journal) in May 2018, found that people consuming eggs regularly were less at risk for heart disease than those who consumed no eggs. The title of the Chinese study is Associations of egg consumption with cardiovascular disease in a cohort study of 0.5 million Chinese adults. Over a half-million Chinese, between the ages of 30 and 79, were recruited across various regions of China and surveyed for egg consumption. Those with histories of cancer, heart disease, stroke, or diabetes were excluded from the study. Those remaining, slightly under a half-million, were followed for several years to determine incidents of cardiovascular disease (CVD) and both ischemic and hemorrhagic strokes. The average egg consumption varied from none to over one a day. The study’s conclusion: "Our findings suggested that daily egg consumption (<1 egg) [actually .8 daily on average] was associated with lower risk of CVD [cardiovascular disease], IHD [ischemic heart disease], MCE [major coronary events], hemorrhagic stroke and ischaemic stroke among Chinese middle-aged adults. Our findings contribute scientific evidence to the dietary guidelines with regard to egg consumption for the healthy Chinese adult." The study noted that morbidity from strokes is higher in China than Western nations where deaths from ischemic heart disease (ISD) are higher. An average egg consumption of .8 could translate to five to six eggs per week. The Chinese study also referenced an earlier smaller Japanese study, the Life Span Study in Japan, and found that “daily egg consumption was associated with a 30% lower risk of total stroke mortality” compared to no or occasional consumption of eggs.
Big Pharma Cannot Explain Why People with Very High LDL Cholesterol Have No Cardiovascular Disease and Live Long Lives
If your hypothesis is that all swans are white, the discovery of one black swan refutes your hypothesis. That is how science works. Or at least that is how science should work. In the real world, scientists are highly adept at explaining away contradictions to their favoured hypotheses. They will use phrases such as, it’s a paradox, or inform you that you didn’t measure the correct things or say there are many other confounding factors – and suchlike. Anyway, accepting that the finding of someone with a very high LDL level, and no detectable atherosclerosis, will always be dismissed – in one way or another – I am still going to introduce you to a ‘case history’ of a seventy-two-year-old man with familial hypercholesterolaemia, who has been studied for many, many, years. Try as they might, the researchers have been unable to discover any evidence for cardiovascular disease (CVD) – of any sort. The paper was called ‘A 72-Year-Old Patient with Longstanding, Untreated Familial Hypercholesterolemia but no Coronary Artery Calcification: A Case Report.’ And just in case you believe this is a single outlier, something never seen before or since, let me introduce you to the Simon Broome registry, set up in the UK many years ago to study what happens to individuals diagnosed with familial hypercholesterolaemia (FH). It is the longest, if not the largest, study on FH in the world. It has mainly been used as one of the pillars in support of the cholesterol hypothesis. However, when you start to look closely at it – fascinating things emerge. One of the most interesting is that people with FH have a lower than expected overall mortality rate – in comparison to the ‘normal’ population. Or, to put this another way. If you have FH, you live longer than the average person.
A recent study connecting increased statin drug use with rising ALS was discussed by Dr. Malcom Kendrick. He had followed earlier similar studies with similar concerns, but this one confirmed Dr. Kendrick’s suspicions. ALS (Amyotrophic lateral sclerosis), is also known as motor neuron disease (MND), or Lou Gehrig’s disease. The study of concern is Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA’s Adverse Event Reporting System. It was published by the journal Drug Safety in April of 2018. The researchers at the University of California (San Diego) and Advera Health Analytics, Inc., Santa Rosa, California teamed up to analyze data from the FDA Adverse Event Reporting System (FAERS) to determine what is known as reporting odds ratios (RORs) involving statin drugs users who have reported ALS symptoms. This study, which allegedly had no outside funding, concluded: "These findings extend previous evidence showing that significantly elevated ALS reporting extends to individual statin agents, and add to concerns about potential elevated occurrence of ALS-like conditions in association with statin usage."
A Pediatric Cardiologist from Georgia has pleaded guilty to illegally targeting teens for a cholesterol drug that was only approved by the FDA for a rare disorder. According to court documents, Dr. Eduardo Montaña colluded with pharmaceutical company Aegerion to sell their drug Juxtapid to teenagers with heart problems, even though the drug was not approved for their conditions. Dr. Montaña violated HIPAA laws of patient privacy by supplying the pharmaceutical company private medical records of 280 teenagers without patient knowledge or consent. Drug company Aegerion was found guilty of criminal wrongdoing in a Massachusetts court. Juxtapid, which received FDA approval in 2012, costs over $330,000 per patient per year, so the drug company had strong financial motives to expand its sales. Dr. Montaña was a willing accomplice in their criminal activities, and reportedly hoped to get a kickback for himself. He requested a $236,000 grant from Aegerion. In the conviction against Aegerion in this case with Dr. Eduardo Montaña, District Judge William G. Young lamented how the U.S. Government allows criminal pharmaceutical companies to get off so easily, and continue doing business. Existing laws that protect pharmaceutical companies apparently prevented Judge Young from automatically issuing the harshest penalty, as the federal government generally strikes a plea bargain deal with the pharmaceutical company to keep them in business. Judge Young wrote: "What is left unexplained is why the government does not simply let Aegerion collapse in disgrace. Surely Aegerion is not too big to fail."
Cardiologist: Millions of People Taking Statin Drugs Will Continue to Have Far Greater Chance of Harm than Benefit
Two recent articles published in the UK mainstream hard copy and online newspaper Express revealed there’s something wrong with cholesterol-lowering statin drug prescription policies, quoting several doctors who claim statins cause more harm than benefit. Dr. Rita Redberg, a cardiologist professor at the San Francisco Medical Center, states: “Unfortunately, until all data is available and discussed with patients, millions of people taking these [statin] drugs will continue to have far greater chance of harm than benefit.” Dr. Rita Redberg's name might be familiar to our readers, because she appeared in an Australian two-part TV news documentary that has often been featured in several Health Impact News articles. Both parts were connected thematically and produced by Dr. Maryanne Demasi, Ph.D. And it was Dr. Demasi’s British Medical Journal (BMJ) article and study review that the Express article was reporting rather favorably with quotes from other doctors supporting her findings. The article’s focus was on the controversy it had ignited regarding the widespread use of cholesterol-lowering statin drugs.
The least publicized actual side effect of cholesterol-lowering statin drugs that complements the dangerous intended effect of reducing cholesterol is they also block CoQ10 production, which is already waning among those aged 40 and older. That’s the age when people begin getting prescribed statins per the newest statin drug guidelines. The irony is that CoQ10 is vital for good heart health! CoQ10 is on high demand from cells in muscle tissue, and the muscle that works the most without rest is the heart. Instead of supplementing CoQ10 when one reaches the 40 year plus mark, he or she will likely be prescribed statin drugs for life as a preventative against cardiovascular disease and heart attack. As statin drugs decrease one’s already lowered CoQ10 production from aging, the heart can get slowly weaker, leading to congestive heart failure. This is when the heart keeps beating, but it is so weak it isn’t strong enough to maintain blood flow throughout to meet the body's needs. Instead of the pain that accompanies a sudden heart attack, gradually one begins to have less and less energy. Excessive tiredness comes in that may be incorrectly attributed to aging or being out of shape. Exercise only further exposes one’s breathing problems. Distended belly and leg swelling also occur. This can go on for years with increasing disability until there is a total heart failure. The newest guidelines for statins almost require physicians to put patients on statins as a preventative practice for life. As the CoQ10 deficiency worsens from statins, the poor patient goes into a debilitating spiral without any recognition to its true cause.
Aggressive lowering of low-density lipoprotein cholesterol (LDL-C) has been the cornerstone of preventative cardiology for decades. Statins are widely used as the go-to solution for the prevention of heart disease owing to their ability to slash LDL-C levels, a ‘surrogate marker’ of cardiovascular disease (CVD). Indeed, statins are one of the most widely prescribed class of drugs in the world. But this phenomenon begs two questions: is the enthusiasm for aggressive lowering of LDL-C justified; and is pharmacotherapy superior to lifestyle intervention? In summary, for many patients at high risk of CVD, one of the safest and most effective ways to reduce the risk of heart attack and stroke is to consume a high fat and low glycaemic load Mediterranean diet and engage in regular exercise. At the very least, exercise interventions are often similar to drug interventions in terms of their mortality benefits in the secondary prevention of coronary heart disease, and do not come with side effects.
As we have reported frequently here at Health Impact News, sales of drugs to lower cholesterol are the top selling drugs of all time. It is a $100 billion a year industry. The cholesterol-lowering drug Lipitor is the best-selling drug of all time, grossing over $140 billion, with no serious close competitors in the history of pharmaceutical drugs. One out of every four Americans over the age of 50 is taking a statin drug to lower their cholesterol. However, these block buster drugs have run through their patent life, and now generics dominate the market. So Big Pharma is looking at new ways to patent new drugs to lower your cholesterol. The latest? A vaccine is being developed to lower your cholesterol. In recent years, class action lawsuits have been stacking up against statin drug manufacturers due to the terrible side effects, including diabetes. Is this another reason for turning to vaccines to "cure" cholesterol? In this country, lawsuits against vaccines are prohibited while civil suits against prescription or over-the-counter drugs are allowed.
The pharmaceutical empire strikes back. After the recent few years of increasing “statin deniers” getting an occasional mainstream media appearance, vested interest parties are coming up with studies to “prove” statins (cholesterol-lowering drugs) are safe. The problem is most folks on the fence, as most are, will be distracted by these studies no matter how biased and without merit they may be. Doctors who know the truth about statins are forced to pick any such statin safety study apart in response in order to straighten out doctors who prescribe statins based on pharmaceutical reps’ presentations and industry biased studies. One such doctor who is outspokenly critical of statin drugs, Scottish General Practitioner (GP) Malcom Kendrick, M.D., recently focused on a Lancet paper that intended to prove side effects from statin drugs were not only greatly exaggerated, but all in the patients' heads. According to the paper, patients were suffering from the “nocebo effect,” due to all the rising information regarding statin side effect symptoms publicly reported. In addition to his analysis of the study and comparisons to other studies, Dr. Kendrick offers his personal and professional experiences of taking patients off statins and watching them recover from torn or ravaged muscles and early onset dementia, among other side effects. Dr. Kendrick’s father, whose side effects had him wheel chair bound until his doctor-son convinced him to quit taking statins is an example he offered. No nocebo effects had them in such terrible shape that was relieved when they got off statins.
A 2017 meta-analysis of 29 studies has concluded that consuming dietary dairy fat has no negative effects on all cause mortality or mortality from cardiovascular disease (CVD) and coronary heart disease (CHD). This includes dairy fats of all types. One of the researchers, Ian Givens of England’s Reading University, commented on the record: “There’s been a lot of publicity over the last 5 to 10 years about how saturated fats increase the risk of cardiovascular disease and a belief has grown up that they must increase the risk, but they don’t.” Actually, dairy and other animal sourced saturated fats have been wrongly condemned as a contributor to obesity and higher cardiovascular risk since Ancel Keys' notorious seven countries study over 50 years ago, which spawned the “lipid theory” of heart disease and obesity.